143 related articles for article (PubMed ID: 30293937)
1. Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study.
Ho CLB; Chowdhury EK; Breslin M; Doust J; Reid CM; Wing LMH; Nelson MR;
J Clin Lipidol; 2019; 13(1):148-155. PubMed ID: 30293937
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.
Chowdhury EK; Owen A; Ademi Z; Krum H; Johnston CI; Wing LM; Nelson MR; Reid CM;
Am J Hypertens; 2014 Feb; 27(2):199-206. PubMed ID: 24249722
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study.
Ho CLB; Breslin M; Doust J; Reid CM; Nelson MR
BMJ Open; 2018 Mar; 8(3):e017723. PubMed ID: 29555790
[TBL] [Abstract][Full Text] [Related]
4. Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Ho CLB; Breslin M; Chowdhury EK; Doust J; Reid CM; Davis BR; Simpson LM; Nelson MR
J Hypertens; 2020 Mar; 38(3):519-526. PubMed ID: 31584517
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive drug class in combination with lipid lowering treatment for primary prevention of cardiovascular disease in the elderly.
Zhou Z; Chowdhury EK; Breslin M; Curtis AJ; Reid CM; Nelson M;
Heart Lung; 2022; 51():40-45. PubMed ID: 34731696
[TBL] [Abstract][Full Text] [Related]
6. Ten-year legacy effects of baseline blood pressure 'treatment naivety' in the Second Australian National Blood Pressure study.
Nelson MR; Chowdhury EK; Doust J; Reid CM; Wing LM
J Hypertens; 2015 Nov; 33(11):2331-7. PubMed ID: 26335432
[TBL] [Abstract][Full Text] [Related]
7. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Hallberg S; Banefelt J; Fox KM; Mesterton J; Johansson G; Levin LÅ; Sobocki P; Gandra SR
Int J Clin Pract; 2016 Mar; 70(3):222-8. PubMed ID: 26799539
[TBL] [Abstract][Full Text] [Related]
9. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
Hero C; Rawshani A; Svensson AM; Franzén S; Eliasson B; Eeg-Olofsson K; Gudbjörnsdottir S
Diabetes Care; 2016 Jun; 39(6):996-1003. PubMed ID: 27208327
[TBL] [Abstract][Full Text] [Related]
10. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy.
Galema-Boers AM; Lenzen MJ; Engelkes SR; Sijbrands EJ; Roeters van Lennep JE
J Clin Lipidol; 2018; 12(2):409-416. PubMed ID: 29398430
[TBL] [Abstract][Full Text] [Related]
12. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
13. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial.
Dagenais GR; Jung H; Lonn E; Bogaty PM; Dehghan M; Held C; Avezum A; Jansky P; Keltai M; Leiter LA; Lopez-Jaramillo P; Toff WD; Bosch J; Yusuf S
J Am Heart Assoc; 2018 Jul; 7(15):. PubMed ID: 30033433
[TBL] [Abstract][Full Text] [Related]
14. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
15. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community.
Lieb W; Enserro DM; Larson MG; Vasan RS
Open Heart; 2018; 5(1):e000722. PubMed ID: 29387429
[TBL] [Abstract][Full Text] [Related]
16. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register.
Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Andersson Sundell K; Eliasson B; Eeg-Olofsson K
BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958300
[TBL] [Abstract][Full Text] [Related]
17. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
18. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
